Allworth Financial LP Buys 3,789 Shares of Zoetis Inc. $ZTS

Allworth Financial LP increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 8.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,179 shares of the company’s stock after acquiring an additional 3,789 shares during the period. Allworth Financial LP’s holdings in Zoetis were worth $7,358,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Savvy Advisors Inc. increased its holdings in Zoetis by 54.0% during the second quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after buying an additional 1,114 shares during the last quarter. Sound Income Strategies LLC lifted its stake in Zoetis by 54.3% in the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after acquiring an additional 152 shares during the last quarter. Canoe Financial LP grew its position in shares of Zoetis by 859.0% in the 2nd quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock valued at $2,085,000 after acquiring an additional 11,975 shares during the period. Strs Ohio acquired a new position in shares of Zoetis during the 1st quarter worth about $22,891,000. Finally, Soros Capital Management LLC raised its holdings in shares of Zoetis by 32.0% in the 1st quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock valued at $2,872,000 after purchasing an additional 4,230 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

NYSE ZTS opened at $120.09 on Wednesday. The firm has a 50-day moving average price of $142.82 and a two-hundred day moving average price of $152.16. Zoetis Inc. has a 12-month low of $117.26 and a 12-month high of $181.85. The company has a market capitalization of $52.92 billion, a P/E ratio of 20.67, a P/E/G ratio of 2.31 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is presently 33.67%.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZTS. UBS Group reduced their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. JPMorgan Chase & Co. decreased their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Stifel Nicolaus set a $140.00 price target on Zoetis in a research note on Tuesday, November 4th. Finally, Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Moderate Buy” and a consensus price target of $182.50.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.